NCT02953496 is a Phase 1 clinical trial of vonapanitase in Peripheral Artery Disease, sponsored by Proteon Therapeutics.

Who is sponsoring NCT02953496?

NCT02953496 is sponsored by Proteon Therapeutics.

What drugs are being tested in NCT02953496?

Interventions in NCT02953496: vonapanitase.

What condition does NCT02953496 study?

NCT02953496 studies Peripheral Artery Disease.

Is NCT02953496 still recruiting?

NCT02953496 is currently withdrawn. Last updated 2 May 2019.

Last reviewed 2019-05-02 · How we verify

NCT02953496

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

Withdrawn Phase 1 Last updated 2 May 2019

What this trial tests

Phase 1 trial testing vonapanitase in Peripheral Artery Disease. Withdrawn.

Timeline

Primary endpoint
30 April 2019

30 April 2019

Quick facts

Lead sponsor	Proteon Therapeutics
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Primary completion	30 April 2019
Estimated completion	30 April 2019
Sites	1 location across United States

Drugs / interventions tested

vonapanitase — full drug profile →

Conditions studied

Peripheral Artery Disease — all drugs for Peripheral Artery Disease →

Sponsor

Proteon Therapeutics — full company profile →

Who can join

Adults 18 to 100, any sex, with Peripheral Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The research study is designed to assess the technical feasibility and safety of percutaneous administration of vonapanitase to the superficial femoral or popliteal artery in patients with PAD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Peripheral Artery Disease

Currently open trials in the same condition.

NCT07374601 — The Value of Super-resolution Ultrasound Imaging for Peripheral Artery Disease · recruiting
NCT06686121 — Improving Mobility After Revascularization in Peripheral Artery Disease · Phase 3 · recruiting
NCT04433572 — Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee · Phase 3 · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT07012070 — Improving Walking Performance in Patients With Peripheral Artery Disease Through Wearable Activity Trackers · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02953496 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Proteon Therapeutics
Last refreshed: 2 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02953496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing